Exosome as a Vehicle for Delivery of Membrane Protein Therapeutics, PH20, for Enhanced Tumor Penetration and Antitumor Efficacy

Yeonsun Hong, Gi Hoon Nam, Eunee Koh, Sangmin Jeon, Gi Beom Kim, Cherlhyun Jeong, Dong-Hwee Kim, Yoosoo Yang, In-San Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

As biochemical and functional studies of membrane protein remain a challenge, there is growing interest in the application of nanotechnology to solve the difficulties of developing membrane protein therapeutics. Exosome, composed of lipid bilayer enclosed nanosized extracellular vesicles, is a successful platform for providing a native membrane composition. This study reports an enzymatic exosome, which harbors native PH20 hyaluronidase (Exo-PH20), which is able to penetrate deeply into tumor foci via hyaluronan degradation, allowing tumor growth inhibition and increased T cell infiltration into the tumor. This exosome-based strategy is developed to overcome the immunosuppressive and anticancer therapy-resistant tumor microenvironment, which is characterized by an overly accumulated extracellular matrix. Notably, this engineered exosome with the native glycosylphosphatidylinositol-anchored form of hyaluronidase has a higher enzymatic activity than a truncated form of the recombinant protein. In addition, the exosome-mediated codelivery of PH20 hyaluronidase and a chemotherapeutic (doxorubicin) efficiently inhibits tumor growth. This exosome is designed to degrade hyaluronan, thereby augmenting nanoparticle penetration and drug diffusion. The results thus show that this is a promising exosome-based platform that harbors not only a membrane-associated enzyme with high activity but also therapeutic payloads.

Original languageEnglish
Article number1703074
JournalAdvanced Functional Materials
Volume28
Issue number5
DOIs
Publication statusPublished - 2018 Jan 31

Fingerprint

Tumors
delivery
Membrane Proteins
vehicles
tumors
penetration
Hyaluronoglucosaminidase
membranes
proteins
Proteins
Membranes
harbors
Hyaluronic Acid
Ports and harbors
platforms
Recombinant proteins
Glycosylphosphatidylinositols
Lipid bilayers
T-cells
infiltration

Keywords

  • cancer therapy
  • doxorubicin
  • exosomes
  • GPI-anchored proteins
  • PH20

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics

Cite this

Exosome as a Vehicle for Delivery of Membrane Protein Therapeutics, PH20, for Enhanced Tumor Penetration and Antitumor Efficacy. / Hong, Yeonsun; Nam, Gi Hoon; Koh, Eunee; Jeon, Sangmin; Kim, Gi Beom; Jeong, Cherlhyun; Kim, Dong-Hwee; Yang, Yoosoo; Kim, In-San.

In: Advanced Functional Materials, Vol. 28, No. 5, 1703074, 31.01.2018.

Research output: Contribution to journalArticle

Hong, Yeonsun ; Nam, Gi Hoon ; Koh, Eunee ; Jeon, Sangmin ; Kim, Gi Beom ; Jeong, Cherlhyun ; Kim, Dong-Hwee ; Yang, Yoosoo ; Kim, In-San. / Exosome as a Vehicle for Delivery of Membrane Protein Therapeutics, PH20, for Enhanced Tumor Penetration and Antitumor Efficacy. In: Advanced Functional Materials. 2018 ; Vol. 28, No. 5.
@article{307de1cfcc9a479594c38a65834dfb4d,
title = "Exosome as a Vehicle for Delivery of Membrane Protein Therapeutics, PH20, for Enhanced Tumor Penetration and Antitumor Efficacy",
abstract = "As biochemical and functional studies of membrane protein remain a challenge, there is growing interest in the application of nanotechnology to solve the difficulties of developing membrane protein therapeutics. Exosome, composed of lipid bilayer enclosed nanosized extracellular vesicles, is a successful platform for providing a native membrane composition. This study reports an enzymatic exosome, which harbors native PH20 hyaluronidase (Exo-PH20), which is able to penetrate deeply into tumor foci via hyaluronan degradation, allowing tumor growth inhibition and increased T cell infiltration into the tumor. This exosome-based strategy is developed to overcome the immunosuppressive and anticancer therapy-resistant tumor microenvironment, which is characterized by an overly accumulated extracellular matrix. Notably, this engineered exosome with the native glycosylphosphatidylinositol-anchored form of hyaluronidase has a higher enzymatic activity than a truncated form of the recombinant protein. In addition, the exosome-mediated codelivery of PH20 hyaluronidase and a chemotherapeutic (doxorubicin) efficiently inhibits tumor growth. This exosome is designed to degrade hyaluronan, thereby augmenting nanoparticle penetration and drug diffusion. The results thus show that this is a promising exosome-based platform that harbors not only a membrane-associated enzyme with high activity but also therapeutic payloads.",
keywords = "cancer therapy, doxorubicin, exosomes, GPI-anchored proteins, PH20",
author = "Yeonsun Hong and Nam, {Gi Hoon} and Eunee Koh and Sangmin Jeon and Kim, {Gi Beom} and Cherlhyun Jeong and Dong-Hwee Kim and Yoosoo Yang and In-San Kim",
year = "2018",
month = "1",
day = "31",
doi = "10.1002/adfm.201703074",
language = "English",
volume = "28",
journal = "Advanced Functional Materials",
issn = "1616-301X",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Exosome as a Vehicle for Delivery of Membrane Protein Therapeutics, PH20, for Enhanced Tumor Penetration and Antitumor Efficacy

AU - Hong, Yeonsun

AU - Nam, Gi Hoon

AU - Koh, Eunee

AU - Jeon, Sangmin

AU - Kim, Gi Beom

AU - Jeong, Cherlhyun

AU - Kim, Dong-Hwee

AU - Yang, Yoosoo

AU - Kim, In-San

PY - 2018/1/31

Y1 - 2018/1/31

N2 - As biochemical and functional studies of membrane protein remain a challenge, there is growing interest in the application of nanotechnology to solve the difficulties of developing membrane protein therapeutics. Exosome, composed of lipid bilayer enclosed nanosized extracellular vesicles, is a successful platform for providing a native membrane composition. This study reports an enzymatic exosome, which harbors native PH20 hyaluronidase (Exo-PH20), which is able to penetrate deeply into tumor foci via hyaluronan degradation, allowing tumor growth inhibition and increased T cell infiltration into the tumor. This exosome-based strategy is developed to overcome the immunosuppressive and anticancer therapy-resistant tumor microenvironment, which is characterized by an overly accumulated extracellular matrix. Notably, this engineered exosome with the native glycosylphosphatidylinositol-anchored form of hyaluronidase has a higher enzymatic activity than a truncated form of the recombinant protein. In addition, the exosome-mediated codelivery of PH20 hyaluronidase and a chemotherapeutic (doxorubicin) efficiently inhibits tumor growth. This exosome is designed to degrade hyaluronan, thereby augmenting nanoparticle penetration and drug diffusion. The results thus show that this is a promising exosome-based platform that harbors not only a membrane-associated enzyme with high activity but also therapeutic payloads.

AB - As biochemical and functional studies of membrane protein remain a challenge, there is growing interest in the application of nanotechnology to solve the difficulties of developing membrane protein therapeutics. Exosome, composed of lipid bilayer enclosed nanosized extracellular vesicles, is a successful platform for providing a native membrane composition. This study reports an enzymatic exosome, which harbors native PH20 hyaluronidase (Exo-PH20), which is able to penetrate deeply into tumor foci via hyaluronan degradation, allowing tumor growth inhibition and increased T cell infiltration into the tumor. This exosome-based strategy is developed to overcome the immunosuppressive and anticancer therapy-resistant tumor microenvironment, which is characterized by an overly accumulated extracellular matrix. Notably, this engineered exosome with the native glycosylphosphatidylinositol-anchored form of hyaluronidase has a higher enzymatic activity than a truncated form of the recombinant protein. In addition, the exosome-mediated codelivery of PH20 hyaluronidase and a chemotherapeutic (doxorubicin) efficiently inhibits tumor growth. This exosome is designed to degrade hyaluronan, thereby augmenting nanoparticle penetration and drug diffusion. The results thus show that this is a promising exosome-based platform that harbors not only a membrane-associated enzyme with high activity but also therapeutic payloads.

KW - cancer therapy

KW - doxorubicin

KW - exosomes

KW - GPI-anchored proteins

KW - PH20

UR - http://www.scopus.com/inward/record.url?scp=85041021263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041021263&partnerID=8YFLogxK

U2 - 10.1002/adfm.201703074

DO - 10.1002/adfm.201703074

M3 - Article

AN - SCOPUS:85041021263

VL - 28

JO - Advanced Functional Materials

JF - Advanced Functional Materials

SN - 1616-301X

IS - 5

M1 - 1703074

ER -